SIBO INFO Blog

In this video, Dr. Pimentel explores advancements in understanding Small Intestinal Bacterial Overgrowth (SIBO) through deep sequencing techniques. The discussion highlights specific bacterial genera and species identified as primary culprits in hydrogen SIBO, challenging previous assumptions about SIBO's composition and pinpointing particular strains linked to common symptoms.
​
Key Discussions and Takeaways:

• Advancements in SIBO: The video discusses the move towards "deeper sequencing," enabling precise identification of the specific bacteria responsible for hydrogen SIBO.
• Primary Bacterial Genera Identified: For hydrogen SIBO patients, Klebsiella and Escherichia are identified as the most significant bacterial genera.
• Dominance of Specific Bacteria in hydrogen SIBO:
  • Klebsiella pneumoniae comprises 18% of gut bacteria in SIBO patients.
  • Escherichia coli accounts for 28% of gut bacteria in SIBO patients.
• Revisiting the understanding of SIBO: The findings suggest that SIBO is not simply a general overgrowth of colon bacteria in the small intestine, but is primarily caused by E. coli and Klebsiella pneumoniae.
• Role of Specific Strains: The discussion indicates that specific strains, such as the K12 strain of E. coli, may directly correlate with common SIBO/IBS symptoms including bloating, abdominal pain, and diarrhea.

In this video, Dr. Pimentel explains the breakthrough test, IBS-Smart, which is the first test that can diagnose Irritable Bowel Syndrome (IBS), using novel antibody testing. When positive, it also diagnoses SIBO. A SIBO breath test would then be needed to find which subtype of SIBO is present (treatments are tailored to SIBO type).

Key Discussion Points

• Revolutionary IBS Diagnosis: The introduction of specific antibodies that now allow for the diagnosis of IBS for the first time.
• Test Generations: A comparison is made between first-generation and the more robust second-generation IBS-Smart test.
• Disease Differentiation: This test is crucial for distinguishing IBS from other gastrointestinal conditions.
• Test Accuracy:
  • The pooled sensitivity for the test is 56%. The speaker clarifies that this is not considered low for diagnosing post-infection IBS, as the maximum possible sensitivity for this specific subtype is 60%.
  • The specificity is very high, characterized by the statement: "If you're positive, you got it."
• Clinical Certainty: The IBS-Smart test is presented as the only available test that can lead to "medical certainty" for IBS diagnosis.

Note: The test only diagnoses IBS and SIBO caused by food poisoning, but no other causes. It's possible to have IBS and/or SIBO from another cause and this test would be negative in that case.

Products Mentioned:

• IBS-Smart test ($25 off with code SIBOINFO25)

In this video Dr. Pimentel explains how food poisoning causes Irritable Bowel Syndrome (IBS), also called post-infectious IBS in this scenario, and Small Intestinal Bacterial Overgrowth (SIBO).

Key Discussions and Takeaways:

• The Pathological Sequence: 
  • Pathogenic bacteria secrete the toxin CDT B.
  • The immune system develops anti-vinculin antibodies.
  • This leads to a reduction in specific nerves (ICC nerves) within the gut.
  • The consequence is stasis of the gut and subsequent bacterial overgrowth.
• Statistical Impact:
  • Approximately 1 in 9 individuals, or 11%, who contract food poisoning go on to develop IBS/SIBO.
  • Modeling based on the prevalence of food poisoning suggests it could account for about two-thirds, or 60%, of all IBS cases, especially IBS-diarrhea.

Navigating prokinetics and GLP-1 Medications: Impact on Gut Motility and SIBO

Key Discussions:

• Prokinetics and GLP-1 Medications:
  • The video addresses the question of whether prokinetic agents, which help move food through the stomach and intestines, are effective or advisable for patients on GLP-1 medications.
  • GLP-1 drugs are noted to slow down gastrointestinal motility as part of their mechanism.
  • Introducing a prokinetic like Prucalopride would likely counteract the GLP-1's intended effect, potentially making it counterproductive, especially for patients investing in expensive weight-loss medication.
  • GLP-1 agonists are described as being very powerful in inhibiting motility, to the extent that prokinetics are unlikely to overcome their effect, rendering their use in this context a waste of money.
• GLP-1 and SIBO Concerns:
  • The discussion examines whether SIBO (Small Intestinal Bacterial Overgrowth) can worsen in patients taking GLP-1s.
  • The advice given is that when a patient reaches their weight loss goal, the GLP-1 can be paused for a period, at which point SIBO could be checked.
  • There can be GI symptom improvement on GLP-1s from the significant reduction in appetite, leading to decreased food intake.
  • Less food consumption generally means less fermentation, which can lead to fewer IBS symptoms.

Key Takeaways:

• Using prokinetic agents alongside GLP-1 medications may not overcome the powerful motility-inhibiting effects of GLP-1s and may be counterproductive and a financial waste.
• GLP-1 medications can lead to a reduction in IBS-like symptoms due to decreased appetite and eating, and subsequent reduced fermentation.
• If SIBO concerns arise while on a GLP-1, it is suggested to address this after pausing the GLP-1 medication, particularly once weight loss goals are met.
  
  

Products mentioned:

• GLP-1 medicines are Ozempic and Wegovy (Semaglutide)
  
• GLP-1 and GIP medicines are Mounjaro and Zepbound (Tirzepatide)
  
• Prucalopride is prescription prokinetic sold as Motegrity (US), Resolor/Resotran (Europe/Canada)

Comparing Glucose and Lactulose for Breath Testing
This video addresses the debate surrounding the use of glucose versus lactulose as substrates in SIBO breath testing, especially in relation to the microbiome and the accuracy of findings.

Key Discussions and Takeaways:

• The Central Question: Why do studies sometimes suggest glucose is better, while clinical practice often favors lactulose? The discussion aims to clarify the differences and the reasoning behind preferring lactulose.
• Lactulose: Strength in Validation and Microbiome Link:
  • The lactulose breath test is highlighted as having been validated against the microbiome in various studies, citing publications like PLOS ONE and Villanueva.
  • A key point is that the amount of lactulose administered (e.g., 10 grams) is understood to be delivered to the colon, with minimal absorption in the upper gastrointestinal tract.
  • Dr. Pimentel believes that with improved, more accurate culture-gathering techniques, lactulose aligns well with the validated "gold standard" of microbiome analysis.
• Concerns with Glucose Testing:
  • A significant concern is that glucose can be absorbed in the mouth, throat, esophagus, and stomach, meaning a variable and potentially lesser amount reaches the small bowel or colon. This absorption rate can differ greatly among individuals.
  • The rapid absorption of glucose may lead to missing a SIBO diagnosis, since there is no substrate left to be fermented by bacteria in the lower portions of small intestine.
  • There is a noted absence of research studies that directly compare the microbiome to a glucose breath test.
  • Older studies favoring glucose are questioned due to the use of less sophisticated culture-gathering techniques at the time, which may not have been the most accurate benchmark.
• Upcoming Definitive Study: The speaker mentions a new study nearing publication that is expected to definitively address which substrate is superior and for whom.
• Current Consensus and Practice:
  • The North American consensus guidelines permit the use of either glucose or lactulose.
  • While acknowledging that some research leans towards glucose being equal to or more specific than lactulose, Dr. Pimentel personally favors lactulose based on the current "hard science."
• The Evolving "Gold Standard": The reliability of older studies is contextualized by the evolution of diagnostic techniques, suggesting that the "gold standard" for microbiome culture was not always as robust as it is now.

Products Mentioned:
Order a lactulose SIBO breath test - options here

Dr. Pimentel discusses the transition phase from an elemental diet back to regular table food, and the underlying principles of gut health and microbiome recovery.

Transitioning Back to Table Food

• Start Simple: When moving from an elemental diet, begin with easy-to-digest foods like soup and sandwiches.
• Avoid Overindulgence: Refrain from immediately consuming heavy or rich meals, such as steak, potatoes, or ribs, especially from places like steakhouses or restaurants known for large portions. These can overwhelm a gut that is still recovering.
• Gradual Reintroduction: It is essential to ease back into solid food over several days to allow the digestive system to adapt.

Understanding Gut Physiology and the Elemental Diet

• Villi Atrophy: During an elemental diet, the villi in the gut lining can become shorter because they are not being used for digestion. This is compared to an arm that shrinks when immobilized in a cast.
• Body Conservation: The human body conserves resources; unused structures tend to diminish.
• Risk of Malabsorption: Reintroducing rich foods too soon after an elemental diet can lead to diarrhea because the atrophied villi are not yet capable of absorbing nutrients effectively.
• Recovery Timeline: While villi can regrow quickly, typically within three to four days, it's important to manage the transition.

Assessing Elemental Diet Effectiveness and Patient Experience

• Don't Rush Judgment: It's advised not to declare victory or failure immediately after completing an elemental diet.
• Observation Period: Patients should wait 10 to 14 days after the elemental diet concludes before assessing its true outcome, as some temporary discomfort in the stomach can occur during this period.
• Anxiety During Transition: There can be anxiety when transitioning back to eating. The advice given is to "breathe, relax, and don't overthink" this phase.

Microbiome Recovery and Research

• Restoring Balance: Once harmful "bad actors" are eliminated from the gut (e.g., through elemental diet), the normal, beneficial flora can re-establish itself.
• Gardening Analogy: This process is likened to pulling weeds from a garden; once the weeds are gone, the desired plants (like tomatoes) can grow vigorously and thrive.
• Research Process: The video touches on the often lengthy process of scientific research, development, publication, and eventual market availability of therapies, acknowledging potential patient frustration with the pace. The goal is to publish and present findings from rigorous, expensive research to inform treatments.
  
  Products mentioned:
  - mBiota Elemental Diet - $25 off code SIBO, $50 off code SIBO50 (one time use)
  - Elemental Diets for SIBO (exclusive pricing at Fullscript)
  

Research on the new mBiota Elemental Diet is discussed.

Effectiveness of the Elemental Diet for Different Gases

• Hydrogen Gas: The new elemental diet demonstrated a high success rate, normalizing hydrogen breath tests for almost every patient. This outcome is noted as being even better than what was observed in the Vivonex study from 2003.
• Methane Gas: It also showed effectiveness for methane, with approximately 70-80% of patients experiencing positive results. This is also considered an improvement compared to findings from the Vivonex study.

Importance of Taste and Patient Compliance

• A critical factor for the success of an elemental diet is its taste and the patient's ability to comply with the regimen.
• The new elemental diet discussed in the video is reported to have good taste, even by individuals who are sensitive tasters.
• Compliance is essential; if a patient cannot tolerate the diet, the investment is lost, and the treatment is ineffective. Feedback from doctors indicates that their patients find this diet tastes better than other elemental diets.

Findings on Hydrogen Sulfide Gas

• While full details are not yet publicly disclosed, Dr. Pimentel mentions ongoing research.
• Dr. Siebecker's dedicated study group, focusing on hydrogen sulfide for three years, found elemental diets  to be successful for hydrogen sulfide gas.

Products mentioned (affiliate link)
– mBiota Elemental Diet - $25 Off with code SIBO

This video delves into the complexities and challenges of diagnosing Small Intestinal Bacterial Overgrowth (SIBO) in individuals taking popular GLP-1/GIP medications like semaglutide and tirzepatide.
Key Discussion Points

• Breath Tests:
  • GLP-1 drugs are known to slow down the digestive system.
  • This slowed transit means that the lactulose or glucose used in breath tests may not move out of the stomach as expected.
  • Consequently, a breath test might show a "flat line," not because SIBO is absent, or there is hydrogen sulfide, but because the substrate is not reaching the small intestine for bacterial fermentation. 
• Aspiration Studies (Endoscopy):
  • Similarly, these medications cause the stomach to empty more slowly, meaning food remains in the stomach longer.
  • This hinders the ability to perform accurate aspiration studies, as food can contaminate the catheter used to collect samples, leading to unreliable results.
• Treatment Efficacy:
  • The slow gastric emptying also raises questions about the effectiveness of treatments like rifaximin when administered to patients on GLP-1/GIP drugs. It's unclear if the antibiotic will successfully leave the stomach or be properly absorbed in the small intestine, to treat SIBO.

Potential Approaches and Unanswered Questions

• Testing Timing: One colleague suggested testing on the morning before taking a dose, or basically, one week after starting the medication, since they are dosed once a week.
• Drug Discontinuation: Another idea proposed is to stop the GLP-1/GIP medication for one to two weeks before undergoing a SIBO test.
• Limited Evidence: While stopping for a minimum of one week is sometimes recommended for SIBO breath tests, there hasn't been enough systematic observation to confirm its effectiveness.

Conclusion
Diagnosing and treating SIBO in patients using GLP-1/GIP drugs presents significant question marks. The impact of these medications on gut function creates a complex scenario where standard diagnostic tools are unreliable.

Products mentioned
– GLP-1 medicines are Ozempic and Wegovy (Semaglutide)
– GLP-1 + GIP medicines are Mounjaro and Zepbound (Tirzepatide)

This video addresses a common concern: are there treatments to do if you experience food poisoning to help prevent getting SIBO (Small Intestinal Bacterial Overgrowth) afterwards.

Steroids

• A single study conducted by a Canadian group from McMaster University investigated this.
  • Participants who experienced food poisoning were given steroids shortly afterward to reduce the immune response.
  • Outcome: This intervention did not prevent the development of IBS/SIBO in the study subjects.
• Why Steroids Didn't Work: Steroids can reduce inflammation temporarily, but they do not prevent the formation of antibodies, which are believed to play a role in the auto-immune reaction leading to post-infectious IBS/SIBO.

Current Understanding and Limitations

• Post-Food Poisoning Actions: Based on current understanding, once food poisoning has occurred and the initial immune response is triggered, there are no guaranteed interventions to prevent subsequent conditions like IBS.
• Lack of Definitive Studies: While there's a strong belief that preventing food poisoning is key, and that prompt treatment of food poisoning might reduce the risk of IBS, robust studies to scientifically prove these strategies are currently lacking.
• Challenges in Research: Conducting trials to test these preventative or early treatment measures is difficult and expensive, which is why definitive answers remain elusive.

Recommended Strategies (Based on current beliefs and limited evidence)

• Prevention is Key:
  
  • The most effective approach is to prevent food poisoning from occurring in the first place, especially when traveling to areas where foodborne illnesses are more common.
    
  • Taking antibiotics as a preventative measure before traveling to high-risk areas is suggested as potentially effective.
• Prompt Treatment: If food poisoning does occur, it is believed that prompt and effective treatment may be beneficial.
  • The rationale is that a shorter duration of food poisoning may lead to a lower likelihood of developing IBS/SIBO.

Conclusion

• While the exact mechanisms and preventative treatments are still areas for further research, prioritizing food safety and seeking timely medical attention for gastrointestinal infections are recommended steps.

This video explores significant findings from recent studies on the human gut microbiome, focusing on fungal components and their implications for health and resistance.

Research on the Small Intestine Fungal (Yeast) Microbiome (Fungiome)

• The team conducted the first-ever shotgun sequencing of the small intestine, providing novel data on the fungal population.
• The study identified that approximately 5% of patients with SIBO (Small Intestinal Bacterial Overgrowth) may also have SIFO (Small Intestinal Fungal Overgrowth).
• Commonly identified fungi include Candida albicans and, occasionally, Candida glabrata, which is noted as being more toxic.
• An interesting correlation was observed: higher levels of Candida albicans were associated with higher levels of SIBO.
• The researchers emphasize that more knowledge is needed to fully interpret these findings.
• A key challenge is the absence of a standard breath test or a reliable indirect measurement for SIFO.

Fungal Production of Penicillin and its Link to Antimicrobial Resistance

• A separate, highly important study identified fungal elements within the normal gut that produce penicillin.
• This finding highlights that fungi can naturally produce penicillin, a known antibiotic.
• When these penicillin-producing fungi are present, an increase in penicillin resistance among gut bacteria was observed.
• This suggests that fungal components may play a role in antibiotic resistance, moving beyond human-induced causes.
• A leading hypothesis arising from this research is that these fungal elements might help control SIBO by producing penicillin locally, thus regulating bacterial populations.